ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Completed · Phase 2

Conditions studied: Breast Cancer, Brain Metastases

In brief

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.

Key facts

Study ID

NCT02048059

Run by

Angiochem Inc

People needed

72

Starts

2014-04-01

Expected to finish

2017-09-01

Last updated by the study team

2020-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old
• Breast cancer
• Recurrent brain metastases from breast cancer
• At least one radiologically-confirmed and measurable metastatic brain lesion ( ≥ 0.5 cm)
• Neurologically stable
• Karnofsky Performance Status (KPS) score ≥ 70
• Adequate hematology and serum chemistry laboratory test results
• Expected survival of ≥ 3 months

You may not qualify if…

• Prior treatment with ANG1005/GRN1005
• Evidence of symptomatic intracranial hemorrhage
• Pregnancy or lactation
• Inadequate bone marrow reserve
• Any evidence of severe or uncontrolled diseases
• Patients with the presence of an infection including abscess or fistulae, or known infection with hepatitis B or C or HIV
• History of interstitial lung disease or evidence of clinically significant interstitial lung disease
• Severe cardiac conduction disturbance
• Central nervous system (CNS) disease requiring immediate neurosurgery intervention
• Known severe hypersensitivity or allergy to paclitaxel or any of its components

Where it is running

• University of Arizona Cancer Center — Tucson, Arizona, United States
• UC San Diego Moores Cancer Center — La Jolla, California, United States
• University of California - LAC Medical Center — Los Angeles, California, United States
• University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California, United States
• UC - Irvine Chao Family Comprehensive Cancer Center — Orange, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• GRU Cancer Center - Georgia Regents University — Augusta, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• University of Maryland - Greenebaum Cancer Center — Baltimore, Maryland, United States
• National Cancer Institute — Bethesda, Maryland, United States
• Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan, United States
• University of New Mexico — Albuquerque, New Mexico, United States
• The Long Islan Brain Tumor Center at Neurological Surgery P.C. — Commack, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Magee Womens Hospital — Pittsburgh, Pennsylvania, United States
• UPMC Cancer Center — Pittsburgh, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Univeristy of Texas Health Science Center in San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.